Literature DB >> 8143100

Gram-negative bacteremia.

S C Schimpff1.   

Abstract

In the 1960s, almost all patients who developed gram-negative bacteremia during granulocytopenia died; death occurred before blood culture results were available in about 50% of cases; many patients received antibiotics that were, at best, suboptimal and frequently inactive against the invading pathogen. In the early 1970s epidemiological studies demonstrated that more than 50% of gram-negative bacteremias were caused by hospital-acquired strains which colonized along the alimentary canal and caused infection in a limited number of locations, especially the pharynx, lungs, colon, and perianum. Surveillance culture studies have demonstrated that among acquired gram-negative bacilli, Pseudomonas aeruginosa will almost invariably proceed to bacteremia if the patient becomes profoundly neutropenic, with Escherichia coli and Klebsiella pneumoniae leading to bacteremia in only a moderate number of patients and other gram-negative bacilli rarely progressing to bacteremia despite colonization. Hence, the leading causes of bacteremia in the granulocytopenic patient are E. coli, K. pneumoniae and P. aeruginosa. Further investigations demonstrated that gram-negative bacilli were acquired from hands, food, and water, thus leading to approaches to infection prevention which included careful handwashing, low-microbial-content diet, and attention to water sources, including ice machines. Another basic approach to infection prevention has been to suppress gram-negative bacilli colonizing the alimentary canal with oral nonabsorbable antibiotics or, more recently and more effectively, with agents such as the fluoroquinolones which, unlike previous regimens, do not concurrently suppress the anaerobic flora, hence maintaining colonization resistance. The third basic approach to infection prevention is to improve the host defense factors, principally by a more rapid return of circulating granulocytes with the use of colony-stimulating factors such as granulocyte/macrophage colony-stimulating factor or granulocyte colony-stimulating factor. As to therapy, the fundamental approach with presumed gram-negative bacteremia is the prompt institution of empiric antibiotic therapy when fever first develops in the setting of granulocytopenia. There is a short "window of opportunity" after which no therapy will be effective. Combinations of antibiotics such as a beta-lactam and an aminoglycoside are used for multiple reasons: to afford coverage in the event the pathogen, proves resistant to one of the agents, to afford a synergistic activity thus improving and prolonging the serum bactericidal activity, and to reduce the development of resistance. However, patients can be divided into two risk groups: those with granulocytopenia and a regenerating bone marrow and those with an aplastic marrow who will have persistent, profound (< 100 microliters) granulocytopenia.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8143100     DOI: 10.1007/bf00326634

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  56 in total

1.  Anti-endotoxin monoclonal antibodies.

Authors:  H S Warren; R L Danner; R S Munford
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

Review 2.  Septic shock: pathogenesis.

Authors:  M P Glauser; G Zanetti; J D Baumgartner; J Cohen
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

3.  Serum bactericidal test in volunteers--a review.

Authors:  S C Schimpff; G L Drusano; H C Standiford
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

5.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

6.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

Review 7.  Epidemiology and clinical impact of gram-negative sepsis.

Authors:  M A Martin
Journal:  Infect Dis Clin North Am       Date:  1991-12       Impact factor: 5.982

8.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

9.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

Review 10.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

Authors:  C S Bryan; K L Reynolds; E R Brenner
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  5 in total

1.  The Multidrug-Resistant Gram-negative Superbugs Threat Require Intelligent Use of the Last Weapon.

Authors:  Zakuan Zainy Deris
Journal:  Malays J Med Sci       Date:  2015-09

2.  Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment.

Authors:  Katerina Katsimpardi; Vassilios Papadakis; Anastasia Pangalis; Agapi Parcharidou; John P Panagiotou; Michael Soutis; Evangelos Papandreou; Sophia Polychronopoulou; Stavros Haidas
Journal:  Support Care Cancer       Date:  2005-11-04       Impact factor: 3.603

Review 3.  Sepsis and septic shock. II. Treatment.

Authors:  J Mayer; R Hajek; J Vorlicek; M Tomiska
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

4.  Pseudomonas aeruginosa phage lysate as an immunobiological agent. 1. Selection of Pseudomonas aeruginosa clinical strains for phage lysate preparation.

Authors:  G Sekaninová; M Kolárová; J Pillich; J Seménka; H Slavíková; D Kubícková; V Zajícová
Journal:  Folia Microbiol (Praha)       Date:  1999       Impact factor: 2.099

Review 5.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.